Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 21st Preview)
-
Personalized cancer mRNA therapy
Merck and Moderna reported a pivotal Phase 3 readout in melanoma for their personalized neoantigen mRNA regimen (Keytruda plus intismeran autogene), meeting the trial’s primary endpoint at interim analysis. The companies said the combination produced a statistically significant and clinically meaningful improvement in recurrence-free survival and also improved distant metastasis-free survival, with no new safety signals reported in the interim data.
-
FDA approvals – gene therapy and bone disease antibody
The FDA cleared Ultragenyx’ one-time AAV8 gene therapy Genglycos (pariglasgene brecaparvovec; DTX-401) for glycogen storage disease type Ia (GSDIa) in patients 8 years and older, marking the first FDA-approved treatment for the underlying enzymatic defect. Separately, Regeneron won FDA approval for Pasatru (garetosmab) to treat fibrodysplasia ossificans progressiva, including reductions in new abnormal bone formation and flare-ups assessed by clinicians.
-
FDA clearance – rare blood cancer siRNA
Silence Therapeutics advanced its rare blood cancer siRNA program after announcing positive Phase II results for divesiran in polycythemia vera (PV). In the SANRECO trial (NCT05499013), Silence said the study met its primary endpoint, with an 88% response rate versus 19% in placebo-controlled groups, translating to more consistent hematocrit control and reduced reliance on frequent phlebotomies.
-
M&A and reverse mergers – market access moves
Ambros Therapeutics agreed to merge with Werewolf Therapeutics in an all-stock deal after Werewolf’s search for strategic alternatives, while raising $150 million to support a Phase 3 path for its lead rare-disease drug candidate. Separately, Fulcrum Therapeutics pursued a public-market route through a $245 million reverse merger with Slate Medicines, with Slate shareholders expected to control the combined company and provide funding for clinical progress in migraine.
-
Clinical strategy – first-line EGFR exon 20 targeted therapy
In a Phase 3 trial published at NEJM.org, Dizal Pharmaceuticals’ sunvozertinib outperformed chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions. The randomized study reported median progression-free survival of 10.3 months with sunvozertinib versus 7.5 months with carboplatin–pemetrexed, alongside higher objective response rates, though grade 3-plus adverse events were more frequent on sunvozertinib than on chemotherapy.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.